<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142880">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848184</url>
  </required_header>
  <id_info>
    <org_study_id>COVPCOV0293</org_study_id>
    <nct_id>NCT01848184</nct_id>
  </id_info>
  <brief_title>A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch</brief_title>
  <acronym>Panacea</acronym>
  <official_title>A Multicentre Prospective Study in Patients Undergoing Ventral Hernia Repair by Open Approach With Intraperitoneal Positioning Using Parietex™ Composite Ventral Patch - Panacea Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sofradim Production</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sofradim Production</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the recurrence rate following the use of PARIETEX™
      Composite Ventral Patch in primary ventral hernia repair by open approach with
      intra‐peritoneal positioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, multinational non‐comparative study.

      Primary Endpoint: Primary hernia recurrence* rate at 24 month follow‐up. The evaluation of
      hernia recurrence will be performed during a physical examination and by ultrasonography.

      Secondary Endpoints: Primary hernia recurrence* rate at 1, 6 and 12 month follow‐up. The
      evaluation of hernia recurrence will be performed during a physical examination and
      confirmed by ultrasonography.

      (*Recurrence is defined as a clinically manifested bulge or a protrusion exacerbated by a
      Valsalva maneuver.)

      Safety Parameters:

      Deep and superficial infection (A Surgical Site Infection (SSI) will be defined in the study
      according to the Centers for Disease Control and Prevention (CDC) criteria for diagnosis of
      SSI).

      Pain / Chronic pain Other post‐operative complications (complications related to visceral
      adhesions, Ileus, seroma, hematoma...) Analgesics consumption Risk factors (severity and
      treatment) Efficacy Parameters: Recurrence of primary ventral hernia Operative time Time of
      the mesh positioning Length of Hospital Stay Ease of use (Mesh handling and manipulability,
      comfort of use …) Return to daily activities/ work Patient satisfaction Patient comfort
      (Carolina's™ Comfort scale (CCS) - QoL questionnaire)

      Visit Schedule:

      Baseline visit (Preoperative) &amp; Operative/Discharge visit

      Post-Op:

      Phone call Day 10

      1 month 6 months 12 months 24 months

      Duration: 12 months recruitment and 24 months follow‐up Up to 12 sites in Europe and the
      United States will be included in this study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary hernia recurrence rate at 24 month follow‐up.</measure>
    <time_frame>24 month follow‐up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The evaluation of hernia recurrence will be performed during a physical examination and by ultrasonography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate at 1, 6 and 12 month follow‐up</measure>
    <time_frame>1, 6 and 12 month follow‐up.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The evaluation of hernia recurrence will be performed during a physical examination and confirmed by ultrasonography.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Parameters</measure>
    <time_frame>at 10 days, 1, 6 and 12 month follow‐up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Deep and superficial infection Pain / Chronic pain Other post‐operative complications (complications related to visceral adhesions, Ileus, seroma, hematoma...) Analgesics consumption Risk factors (severity and treatment)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hernia</condition>
  <arm_group>
    <arm_group_label>PARIETEX™ Composite Ventral Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PARIETEX™ Composite Ventral Patch for ventral hernia repair</intervention_name>
    <arm_group_label>PARIETEX™ Composite Ventral Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients (adult ≥ 18 years) at participating centres undergoing primary ventral
             hernia repair with the device by open approach

          -  Signed informed consent form by the patient or the legally authorized representative

          -  Intraoperative inclusion criteria :Size of the defect: ≤ 4 cm

        Exclusion Criteria:

          -  Emergency procedure

          -  Current participation in other trials

          -  History of previous hernia at the same location.

          -  Pregnant women: Women who are known or suspected to be pregnant, or who are planning
             to become pregnant during the study follow‐up period

          -  Patient &lt; 18 years

          -  BMI &gt; 35

          -  ASA score ≥ 4

          -  The investigator determined that the patient will not be able to comply with the
             required follow‐up visits
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Berrevoet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ghent (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars N Jørgensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, University of Copenhagen (Denmark)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Doerhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgicare of MO (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Hopson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hernia Centers of Excellence, VA (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric KULLMAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicinskt Centrum i Linköping (Sweden)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco G MUZI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, University Hospital Tor Vergata, Roma (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon NIENHUIJS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis, EJ EINDHOVEN (The Netherlands)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip E Muysoms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algemene Heelkunde, AZ Maria Middelares Ghent (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Tollens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imelda Hospital, Bonheiden (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Leblanc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Our Lady of the Lake Regional Medical Center, LA (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monmouth Medical Center, NJ (United States)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne MARTINELLA, PhD</last_name>
    <phone>+33 04 74 08 90 00</phone>
    <phone_ext>13 34</phone_ext>
    <email>Corinne.Martinella@covidien.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Traci Frye</last_name>
    <email>Traci.Frye@covidien.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>78080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Leblanc, MD</last_name>
      <phone>225-769-5656</phone>
    </contact>
    <investigator>
      <last_name>Karl Leblanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgicare of Missouri</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Doerhoff, MD</last_name>
      <phone>573-659-5500</phone>
    </contact>
    <investigator>
      <last_name>Carl Doerhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Schwartz, MD</last_name>
      <phone>732-923-6300</phone>
    </contact>
    <investigator>
      <last_name>Mark Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hernia Centers of Excellence</name>
      <address>
        <city>Yorktown</city>
        <state>Virginia</state>
        <zip>23692</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Hopson, MD</last_name>
      <phone>757-846-4335</phone>
    </contact>
    <investigator>
      <last_name>Steven Hopson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Surgery - Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Tollens, MD</last_name>
      <phone>0032474806828.</phone>
      <email>algheelkunde1@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Tim Tollens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frederik BERREVOET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Algemene Heelkunde AZ Maria Middelares Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filip E Muysoms, MD</last_name>
      <phone>003292607181</phone>
      <email>filip.muysoms@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Filip E Muysoms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Surgery K, Bispebjerg Hospital, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars N Jørgensen, MD</last_name>
      <phone>+45 35316441</phone>
      <email>LNJ01@bbh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lars N Jørgensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. ERIC KULLMAN</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58224</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC KULLMAN, Dr.</last_name>
      <phone>+46 13 460 10 00</phone>
      <email>eric.kullman@medcentrum.se</email>
    </contact>
    <investigator>
      <last_name>ERIC KULLMAN, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 26, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARIETEX Composite Ventral Patch</keyword>
  <keyword>PCO VP OR PCOVP</keyword>
  <keyword>Primary ventral hernia repair</keyword>
  <keyword>Panacea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
